Articles related to SGLT2 INHIBITORS

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

A recent randomized controlled trial found that ertugliflozin treatment was associated with a significant reduction in the yearly rate of sustained ventricular arrhythmias (3.5 vs 13.3 events) compared to placebo in patients with heart failure and implantable cardioverter-defibrillators.

Recent research comparing SGLT2 inhibitors and dulaglutide in older patients with type 2 diabetes suggests a potential difference in dementia risk. The study estimated a risk ratio of 0.81 (CI, 0.56 to 1.16) for SGLT2 inhibitors compared to dulaglutide.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

In a rigorous study involving 6,522 patients, empagliflozin, when administered post-acute myocardial infarction, demonstrated a reduction in first hospitalizations due to heart failure, although it did not significantly alter overall survival rates compared to placebo.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.